Hana Biosciences initiated a multi-center Phase II trial of Marqibo in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). This study is designed to support a Phase III trial of Marqibo for the treatment of ALL. The Phase II open-label study will assess efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Secondary objectives are evaluation of safety and disease-free survival. This study is the Phase II portion of an ongoin...